A Phase 1b Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Pharmacokinetics of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Afimetoran (Primary)
- Indications Cutaneous lupus erythematosus; Discoid lupus erythematosus
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 15 Jun 2024 Results assessing the pharmacodynamic effects of afimetoran , presented at the 25th Annual Congress of the European League Against Rheumatism
- 15 Nov 2023 Results of the safety, tolerability, and exploratory efficacy , presented at the ACR Convergence 2023
- 08 May 2023 Status changed from active, no longer recruiting to completed.